【188BET】出金条件超激甘！入金不要ボーナス20ドルの ...

About NCVC About NCVC About NCVC TOP The Center's Mission Organization History of the NCVC Location News Releases Close Hospital Hospital Hospital TOP About the Hospital The Group of Treatment Close Research Institute Research Institute Research Institute TOP About the Research Institute Departments Office for the Promotion of Diversity and Inclusion Research Institute and Open Innovation Center Brochure Close Open Innovation Center Open Innovation Center Open Innovation Center TOP Research Institute and Open Innovation Center Brochure Close Pamphlet National Cerebral and CardiovascularCenter Hospital Res. Inst. OICOpen Innovation Center Access Background White Black Japanese Access Menu National Cerebral and Cardiovascular Center TOP About NCVC News Releases Dapagliflozin 5 mg daily suppressed cardiovascular events in patients with chronic heart failure and type 2 diabetes mellitus About NCVC Dapagliflozin 5 mg daily suppressed cardiovascular events in patients with chronic heart failure and type 2 diabetes mellitus  Diabetes mellitus is well known to cause kidney disease and cardiovascular disease. Dapagliflozin, an SGLT2 (sodium-glucose co-transporter 2) inhibitor, has recently been marketed for treating diabetes and has been shown to improve not only diabetes but also heart failure and renal failure. However, it has been unclear whether dapagliflozin improves renal dysfunction when used in patients with both diabetes and heart failure. The DAPPER study was conducted with the National Cardiovascular Center as the principal investigator, with 294 patients participating from 18 facilities in Japan. In this study, we investigated whether dapagliflozin suppresses urinary albumin excretion, a sensitive marker of kidney damage, and whether it also suppresses cardiovascular events in patients with chronic heart failure and type 2 diabetes mellitus. This study was conducted as a multicenter, randomised, open-label, standard-treatment control, parallel-group comparison with two years of follow-up. The recommended dose of dapagliflozin for heart failure is 10 mg. However, in this study, dapagliflozin was administered at either 5 mg or 10 mg.The results showed that 87.7% of patients in the dapagliflozin group received 5 mg at the end of the 2-year observation period. Although dapagliflozin did not reduce urinary albumin excretion, the primary endpoint, the secondary endpoint of cardiovascular events (cardiovascular death or hospitalisation for cardiovascular events and additional heart failure medication) was reduced in the dapagliflozin group compared to the standard treatment group (see Figures 1 and 2).This is the first report that dapagliflozin administration centered on 5 mg suppressed cardiovascular events in patients with chronic heart failure and type 2 diabetes mellitus. The results of this study are expected to provide valuable insight into treatment strategies for patients with type 2 diabetes mellitus and chronic heart failure. They are expected to make a significant contribution to clinical practice.Publication InformationAuthors: Fumiki Yoshihara, Miki Imazu, Ichiro Sakuma, Yukio Hiroi, Hisao Hara, Osamu Okazaki, Chizuru Ishiguro, Chisato Izumi, Teruo Noguchi, Toshihiko Shiraiwa, Norio Nishioka, Kenshi Fujii, Katsuomi Iwakura, Osamu Tomonaga, Koichi Kobayashi, Masahiro Takihata, Kazuhiko Yumoto, Hiroyuki Takase, Toshiharu Himi, Ikki Shimizu, Tsutomu Murakami, Kenji Wagatsuma, Katsuhiko Sato, Takeyuki Hiramatsu, Satoshi Akabame, Shiro Hata, Masanori Asakura, Takanori Kawabata, Katsuhiro Omae, Shin Ito, Masafumi Kitakaze, on behalf of the DAPPER InvestigatorsTitle: DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trialJournal: eClinicalMedicineAcknowledgmentsThe following organisations financially supported this research;AstraZeneca K. K., Ono Pharmaceutical Co., Ltd.last updated：2023/11/28 (Corporate number:3120905003033) 6-1 Kishibe-Shimmachi, Suita, Osaka, 564-8565, Japan TEL：81-6-6170-1070 Access Copyright © National Cerebral and Cardiovascular Center All rights reserved. Site setting Font-size Normal Large Background White Black Japanese English